Using analysis from an open-label, long-term treatment study of the RNS ® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal ...

Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is currently being evaluated for the treatment of ...

Reference: Abbott JA, Wen H, Liu B, et al. Allosteric inhibition of NMDA receptors by low dose ketamine. Mol Psychiatry. 2024 ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

Skye started enrolling patients in its Phase 2 study of nimacimab in August 2024. Nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, is a negative allosteric modulator that acts as both ...